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An 81-year-old man, admitted with lumbago and pollakisuria, was diagnosed to have stage D2 
prostate cancer (T3N2MI). Although the serum level of prostate specific antigen (PSA) was 3,560 
ng/ml, serum testosterone (55.6 ng/dl) and luteinizing hormone (LH, 0.8 mIU/ ml) levels were very 
low. Detailed inquiry of the patient revealed a daily intake of patent medicine containing 6-9 mg 
methyltestosterone for the past 30 years. He was treated by surgical castration and oral 
chlormadinone acetate. We advised him not to take such androgenic drugs. The disease has been 
well controlled for 7 months. 
We stress the importance of checking medication habits of patients with prostate cancer, especially 
androgen-containing drugs which can be purchased without a physician's prescription. A low serum 
LH level may be an important finding indicating the intake of androgenic drugs. 
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INTRODUCTION 
Prostate cancer is a representative hormone-
dependent cancer. Surgical or medical castration 
has been one of the important treatment options since 
the report by Huggins and Hodges in 1941') 
Withdrawal of androgen clearly suppresses the cancer 
growth and relieves the patient's symptoms. We 
encountered a patient with prostate cancer with 
multiple bone metastases who had been taking tablets 
containing methyltestosterone. 
CASE REPORT 
On April 12, 1996, an SI-year-old man was 
admitted to our hospital with the complaints of 
lumbago and pollakisuria. The past medical history 
was unremarkable. On digital rectal examination 
(DRE), a hen's egg-sized hard prostate with irregular 
surface was palpated. Blood chemistry examination 
disclosed elevated alkaline phosphatase (ALP). The 
serum level of prostate specific antigen (PSA, Delfia) 
was 3,560 ng/ml, but the total testosterone (55.6 
ng/dl, normal range 250-1,100) and the luteinizing 
hormone (LH, O.S mIU/ml, normal range 1.8-5.2) 
levels were very low. Transrectal ultrasound guided 
transrectal prostate needle biopsy revealed well-
differentiated adenocarcinoma. Radiographs of the 
chest, lumbar vertebrae, and pelvis revealed multiple 
bone metastases. Pelvic computed tomography scan 
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Change of serum PSA, testosterone 
and luteinizing hormone (LH) levels 
after the treatment. The PSA level 
was lowered and the LH level rose 
markedly. 
which suggested extracapsular and seminal vesicle 
invasion. There was a swollen lymph node in the 
right pelvis measuring 3 cm in diameter. The 
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clinical stage was determined to be T3N2Ml, stage 
D2. Administration of 100 mg of chlormadinone 
acetate was started on April 17, and a bilateral 
orchiectomy was performed on April 26. On April 
30, we became aware that the patient had been taking 
tablets of patent medicine which contained 
methyltestosterone, amino acids, several vitamins 
and some Chinese medicines for about 30 years. 
Each tablet contained 1 mg of methyltestosterone, 
and he had been taking 3 tablets 2 or 3 times daily. 
He followed our advise to stop taking them. His 
serum PSA level was lowered and LH level rose (Fig. 
1); DRE disclosed that his prostate had diminished in 
size. 
DISCUSSION 
Prostate cancer is a representative hormone-
dependent cancer. Testosterone, 95% of which is 
synthesized in the testes, is the major serum androgen 
stimulating prostatic growth2) Autopsy studies 
have revealed that patients with cirrhosis of the liver, 
who had an estrogen level higher than normal, have 
lower rates of prostate cancer than age-matched 
controls3) 
Methyltestosterone, (17 fJ-hydroxy-17 a-methyl-
androst-4-en-3-one), is an orally effective synthetic 
androgen, which has been shown to have 
considerably higher activity than testosterone 4). 
Shin ohara et a1.5) reported that after administration 
of 10 mg methyltestosterone orally in eight healthy 
male subjects, the average highest serum level of 
methyltestosterone was 23.6 ng/ml and the mean half 
life value was 2.29 hours. Since this patient had been 
taking 6 to 9 mg-of methyltestosterone every day for 
30 years, his serum methyltestosterone level is 
speculated to have been maintained at a high level 
during this period. It is not certain whether the 
prostate cancer in this patient was induced by this 
drug or not. Actually, there are many reports that 
the plasma level of testosterone was not significantly 
different between prostate cancer patients and 
controls6- 8) In this patient, the cancer cells were 
proliferating rapidly even though the serum 
testosterone level was very low. However, androgen 
withdrawal (including tablets containing 
methyltestosterone) markedly reduced the serum PSA 
level and prostate size, which indicated that the 
cancer cells were not hormone-independent. His 
serum LH level was low despite the low serum 
testosterone before the treatment, indicating the 
presence of a substance which had strong androgenic 
action. Therefore, his cancer cells may have been 
activated mainly by the oral methyltestosterone. 
Had we not become aware that he was taking these 
tablets and had he continued to take them after the 
bilateral orchiectomy, his prosate cancer would have 
progressed further. 
Such preparations can be easily purchased without 
a physician's prescription. Also, elderly persons 
tend to have many medications prescribed by other 
physicians. We stress the importance of checking all 
the patient's medication habits, and to measure the 
serum testosterone level before beginning the 
treatment in patients with prostate cancer. The 
possibility of intake of androgenic medicine should 
also be considered when the cancer shows regrowth in 
spite of hormonal therapy. 
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症例 は81歳男 性.腰 痛 と頻尿 を主訴 に当院 に入 院
し,前 立 腺癌stageD2(T3N2M1)と診 断 され た.
血清PSAは3,560ng/mlと著 し く高値 で あったが,
血 清 テ ス ト ス テ ロ ン は55.6ng/dl,LHは0.8
mIU/mlと著 しく低値 で あった.患 者 の詳細 な問診
に よ り,6'-9mgのメチ ルテ ス トステ ロ ンを含 む内
服薬 を毎 日30年間にわた り服用 していた ことが判 明 し
た.そ の内服 を厳禁 し,酢 酸 クロルマジ ノンの内服 と
両側精巣摘除術 を施行 した.そ の後7カ 月間,前 立腺
癌 のコ ン トロールは良好であ る.
この症例 によ り,前 立腺癌患者の内服薬,特 に医師
の処方が な くとも手 に入 るアン ドロゲ ンを含 む薬の確
認 の重要性 を再認 識 させ られ た.血 清LHが 低 いの
が重要 なポイ ン トであ る.
(泌尿紀要43:791-793,1997)
